Incyte

Zynyz (retifanlimab) is a PD-1 checkpoint inhibitor from Incyte for two rare cancers. With carboplatin and paclitaxel it is a first-line treatment for advanced squamous cell carcinoma of the anal canal, and as monotherapy it treats metastatic or locally advanced Merkel cell carcinoma.

Retifanlimab-dlwr is a monoclonal antibody given by intravenous infusion that targets PD-1, an off-switch on T cells. Many cancers display the ligands

Jakafi (ruxolitinib) is a Janus kinase inhibitor from Incyte that blocks JAK1 and JAK2, calming overactive immune and blood-cell signalling. It treats myelofibrosis, polycythaemia vera, and both acute and chronic graft-versus-host disease when other therapies have not worked.

Ruxolitinib is a tablet that blocks two enzymes inside cells called JAK1 and JAK2. These enzymes carry messages from the cell surface to the DNA, tell